SG11202108303SA - Inhibition of unintended mutations in gene editing - Google Patents

Inhibition of unintended mutations in gene editing

Info

Publication number
SG11202108303SA
SG11202108303SA SG11202108303SA SG11202108303SA SG11202108303SA SG 11202108303S A SG11202108303S A SG 11202108303SA SG 11202108303S A SG11202108303S A SG 11202108303SA SG 11202108303S A SG11202108303S A SG 11202108303SA SG 11202108303S A SG11202108303S A SG 11202108303SA
Authority
SG
Singapore
Prior art keywords
deaminase
fragment
seq
fusion protein
site
Prior art date
Application number
SG11202108303SA
Other languages
English (en)
Inventor
Jia Chen
Bei Yang
Li Yang
Xingxu Huang
Lijie Wang
Original Assignee
Univ Shanghai Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Shanghai Technology filed Critical Univ Shanghai Technology
Publication of SG11202108303SA publication Critical patent/SG11202108303SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/85—Fusion polypeptide containing an RNA binding domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21111—Aqualysin 1 (3.4.21.111)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22044—Nuclear-inclusion-a endopeptidase (3.4.22.44)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04004—Adenosine deaminase (3.5.4.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04005—Cytidine deaminase (3.5.4.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202108303SA 2019-02-02 2020-02-03 Inhibition of unintended mutations in gene editing SG11202108303SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019074577 2019-02-02
PCT/CN2020/074218 WO2020156575A1 (en) 2019-02-02 2020-02-03 Inhibition of unintended mutations in gene editing

Publications (1)

Publication Number Publication Date
SG11202108303SA true SG11202108303SA (en) 2021-08-30

Family

ID=71841894

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108303SA SG11202108303SA (en) 2019-02-02 2020-02-03 Inhibition of unintended mutations in gene editing

Country Status (12)

Country Link
US (3) US11384353B2 (cg-RX-API-DMAC7.html)
EP (1) EP3918083A4 (cg-RX-API-DMAC7.html)
JP (3) JP7518549B2 (cg-RX-API-DMAC7.html)
KR (2) KR102964723B1 (cg-RX-API-DMAC7.html)
CN (4) CN116656676A (cg-RX-API-DMAC7.html)
AU (3) AU2020214090B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021015092A2 (cg-RX-API-DMAC7.html)
CA (1) CA3128283A1 (cg-RX-API-DMAC7.html)
IL (1) IL285194A (cg-RX-API-DMAC7.html)
SG (1) SG11202108303SA (cg-RX-API-DMAC7.html)
WO (1) WO2020156575A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA202105895B (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4244369A4 (en) * 2020-11-12 2024-10-16 Shanghaitech University GENOME EDITING OF IMPROVED EFFICIENCY AND ACCURACY
CN112575014B (zh) * 2020-12-11 2022-04-01 安徽省农业科学院水稻研究所 一种碱基编辑器SpCas9-LjCDAL1及其构建和应用
CN115161316B (zh) * 2021-04-02 2025-12-23 上海科技大学 一种引导编辑工具、融合rna及其用途
EP4314308A4 (en) * 2021-04-02 2026-05-20 Univ Shanghai Technology GENE THERAPY FOR THE TREATMENT OF BETA-HEMOGLOBINOPATHIES
EP4330389A4 (en) * 2021-04-30 2025-04-30 Alnylam Pharmaceuticals, Inc. RISC REORIENTATION FOR RNA EDITING
US12123006B2 (en) * 2021-05-18 2024-10-22 Shanghaitech University Base editing tool and use thereof
WO2023283092A1 (en) * 2021-07-06 2023-01-12 Prime Medicine, Inc. Compositions and methods for efficient genome editing
US20250019724A1 (en) * 2021-11-18 2025-01-16 Correctsequence Therapeutics Regeneration of surface antigen-negative cells
KR102667508B1 (ko) * 2022-02-08 2024-06-11 주식회사 툴젠 프라임 에디팅 시스템을 이용한 게놈 편집의 과정에서 발생 가능한 오프 타겟을 예측하는 방법
WO2023155901A1 (en) * 2022-02-17 2023-08-24 Correctsequence Therapeutics Mutant cytidine deaminases with improved editing precision
CN119998446A (zh) 2022-06-07 2025-05-13 斯克里贝治疗公司 用于靶向pcsk9的组合物和方法
WO2024012435A1 (en) 2022-07-11 2024-01-18 CorrectSequence Therapeutics Co., Ltd Gene editing systems and methods for treating hereditary angioedema
WO2024042489A1 (en) 2022-08-25 2024-02-29 LifeEDIT Therapeutics, Inc. Chemical modification of guide rnas with locked nucleic acid for rna guided nuclease-mediated gene editing
EP4608979A1 (en) * 2022-10-28 2025-09-03 CorrectSequence Therapeutics (Shanghai) Co., Ltd Gene editing systems and methods for reducing immunogenicity and graft versus host response
IL320573A (en) 2022-11-04 2025-07-01 Life Edit Therapeutics Inc Developed adenine deaminases and RNA-guided nuclease fusion proteins with internal insertion sites and methods of use
WO2024109745A1 (en) * 2022-11-21 2024-05-30 CorrectSequence Therapeutics Co., Ltd Gene editing systems and methods for treating hbv infection
EP4622662A1 (en) * 2022-11-23 2025-10-01 Amber Bio Inc. Gene-modifying endonucleases
WO2024127369A1 (en) 2022-12-16 2024-06-20 LifeEDIT Therapeutics, Inc. Guide rnas that target foxp3 gene and methods of use
WO2024127370A1 (en) 2022-12-16 2024-06-20 LifeEDIT Therapeutics, Inc. Guide rnas that target trac gene and methods of use
CN116286740A (zh) * 2023-02-24 2023-06-23 四川大学华西医院 碱基编辑器和引导编辑器及构建与应用
WO2024178397A2 (en) 2023-02-24 2024-08-29 Elevatebio Technologies, Inc. Modified immune effector cells and methods of use
CN121100181A (zh) * 2023-05-26 2025-12-09 正序(上海)生物医药科技有限公司 基因编辑系统及其用途
EP4750890A2 (en) 2023-07-27 2026-06-03 Life Edit Therapeutics, Inc. Rna-guided nucleases and active fragments and variants thereof and methods of use
EP4780862A1 (en) * 2023-09-21 2026-07-29 Shanghaitech University Rna editing systems of high efficiency and specificity
WO2025081042A1 (en) 2023-10-12 2025-04-17 Renagade Therapeutics Management Inc. Nickase-retron template-based precision editing system and methods of use
CN122422501A (zh) 2023-10-18 2026-07-17 生命编辑治疗股份有限公司 Rna引导的核酸酶及其活性片段和变体以及使用方法
CN117092084B (zh) * 2023-10-20 2024-01-12 浙江迪福润丝生物科技有限公司 Wnv蛋白酶抑制剂的筛选方法和抑制效果评价方法
WO2025140399A1 (en) * 2023-12-26 2025-07-03 Correctsequence Therapeutics (Shanghai) Co., Ltd Gene editing systems and methods for treating cardiovascular disease
WO2025174908A1 (en) 2024-02-12 2025-08-21 Life Edit Therapeutics, Inc. Novel rna-guided nucleases and proteins for polymerase editing
WO2025185623A1 (en) * 2024-03-04 2025-09-12 Shanghaitech University Virus-like particles for gene editing
TW202617985A (zh) 2024-06-25 2026-05-01 美商生命編輯治療學公司 新穎反轉錄酶及其用途
WO2026026929A1 (en) * 2024-07-31 2026-02-05 Correctsequence Therapeutics (Shanghai) Co., Ltd Gene editing systems and methods for treating obesity and metabolic dysfunction and associated diseases
CN118995709B (zh) * 2024-08-23 2026-08-07 东北农业大学 一种提高基因编辑效率的重组型pegRNA及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6445314A (en) 1987-04-16 1989-02-17 Res Corp Technologies Inc Antitumoral
US8288094B2 (en) 2008-04-09 2012-10-16 Institut Pasteur APOBEC3 mediated DNA editing
US8399219B2 (en) * 2009-02-23 2013-03-19 Cytomx Therapeutics, Inc. Protease activatable interferon alpha proprotein
CN111206032B (zh) * 2013-12-12 2024-07-19 布罗德研究所有限公司 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
WO2015089473A1 (en) * 2013-12-12 2015-06-18 The Broad Institute Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
US20150166984A1 (en) * 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
CN105886498A (zh) * 2015-05-13 2016-08-24 沈志荣 CRISPR-Cas9特异性敲除人PCSK9基因的方法以及用于特异性靶向PCSK9基因的sgRNA
WO2017070632A2 (en) * 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
EP3445853A1 (en) * 2016-04-19 2019-02-27 The Broad Institute, Inc. Cpf1 complexes with reduced indel activity
WO2018052247A1 (ko) * 2016-09-13 2018-03-22 주식회사 툴젠 시토신 디아미나제에 의한 dna에서의 염기 교정 확인 방법
US11192929B2 (en) * 2016-12-08 2021-12-07 Regents Of The University Of Minnesota Site-specific DNA base editing using modified APOBEC enzymes
KR102569848B1 (ko) * 2016-12-23 2023-08-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Pcsk9의 유전자 편집
CN108342387B (zh) 2017-01-24 2021-09-24 谭旭 Pcsk9抑制剂类降血脂药的递送系统和生物制剂
JP7277052B2 (ja) * 2017-02-22 2023-05-18 クリスパー セラピューティクス アーゲー プロタンパク質転換酵素サブチリシン/ケキシン9型(pcsk9)関連障害の処置のための組成物および方法
IL306092A (en) * 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
WO2018208998A1 (en) * 2017-05-10 2018-11-15 The Regents Of The University Of California Directed editing of cellular rna via nuclear delivery of crispr/cas9
CA3063733A1 (en) * 2017-05-25 2018-11-29 The General Hospital Corporation Base editors with improved precision and specificity
CN109136272A (zh) 2017-06-15 2019-01-04 中山大学 用于特异性修复人hbb基因突变的碱基编辑系统、方法、试剂盒及其在人生殖系中的应用
SG11201912024RA (en) * 2017-07-31 2020-02-27 Sigma Aldrich Co Llc Synthetic guide rna for crispr/cas activator systems
CN109021111B (zh) * 2018-02-23 2021-12-07 上海科技大学 一种基因碱基编辑器

Also Published As

Publication number Publication date
JP2026012727A (ja) 2026-01-27
AU2020214090A1 (en) 2021-09-16
ZA202105895B (en) 2024-07-31
ZA202212490B (en) 2024-09-25
EP3918083A1 (en) 2021-12-08
KR20260067381A (ko) 2026-05-12
AU2020214090B2 (en) 2022-09-15
US11840685B2 (en) 2023-12-12
AU2025256226A1 (en) 2025-11-13
JP7518549B2 (ja) 2024-07-18
WO2020156575A1 (en) 2020-08-06
CN116286802A (zh) 2023-06-23
CN116656676A (zh) 2023-08-29
US11384353B2 (en) 2022-07-12
AU2022287550B2 (en) 2025-07-24
JP2024109660A (ja) 2024-08-14
KR20210126042A (ko) 2021-10-19
US20220064626A1 (en) 2022-03-03
US20240026342A1 (en) 2024-01-25
BR112021015092A2 (pt) 2022-10-11
JP2022526695A (ja) 2022-05-26
CA3128283A1 (en) 2020-08-06
EP3918083A4 (en) 2023-03-29
KR102964723B1 (ko) 2026-05-14
US20230094769A1 (en) 2023-03-30
CN116355966A (zh) 2023-06-30
AU2022287550A1 (en) 2023-02-02
IL285194A (en) 2021-09-30
CN113661248A (zh) 2021-11-16
JP7761294B2 (ja) 2025-10-28
CN113661248B (zh) 2022-09-16

Similar Documents

Publication Publication Date Title
US11840685B2 (en) Inhibition of unintended mutations in gene editing
US12203077B2 (en) Fusion proteins for improved precision in base editing
AU2017204909B2 (en) Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
US10011850B2 (en) Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
AU2006272634B2 (en) Targeted integration and expression of exogenous nucleic acid sequences
AU2016316845A1 (en) Engineered CRISPR-Cas9 nucleases
KR20180069898A (ko) 핵염기 편집제 및 그의 용도
KR20250075667A (ko) 신규한 아데닌 탈아미노효소 변이체 및 이를 사용한 염기 교정 방법
BR112019019655A2 (pt) editores de nucleobase que compreendem proteínas de ligação a dna programáveis por ácido nucleico
HK40098968A (en) A pair of helper guide rna/guide rna for editing a human pcsk9 nucleic acid sequence
EA049101B1 (ru) Ингибирование непредусмотренных мутаций при редактировании генов
HK40058912A (en) Inhibition of unintended mutations in gene editing
HK40058912B (en) Inhibition of unintended mutations in gene editing
CA3268573A1 (en) Novel adenine deaminase variants and a method for base editing using the same
HK40018020B (en) Fusion proteins for improved precision in base editing
HK40018020A (en) Fusion proteins for improved precision in base editing